Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Controlled drugs

NICE publishes draft scope for new guideline on cannabis-based products for medicinal use

The National Institute for Health and Care Excellence (NICE) has published a draft scope for its upcoming guidelines on cannabis-based products for medicinal use.

The guideline scope, which is out for consultation between 13 November 2018 and 4 December 2018, is aimed primarily at healthcare professionals prescribing cannabis-based medicinal products, or those taking care of people taking cannabis-based medicinal products. 

The document considers the use of these products in line with the General Medical Council’s guidance on prescribing unlicensed medicines for people with chronic pain, intractable nausea and vomiting, spasticity and severe treatment-resistant epilepsy.

As part of this, NICE draws attention to its existing published guidance for the management of multiple sclerosis, epilepsy, cerebral palsy, Parkinson’s disease, cancer and motor neurone disease, which may be relevant.

The document notes that smoked cannabis and cannabis supplements, such as those marketed as food products, are excluded from the guideline. 

Ultimately the NICE guidance, which is due to be published in October 2019, will look at the effectiveness and safety of cannabis-based medicinal products, taking into consideration the clinical and cost effectiveness in relation to side effects, potential interactions and overall risks.

It will also look at decision-making and the support needed to help prescribers and patients make decisions about cannabis-based medicinal products, as well as the prescribing requirements, such as who should be able to prescribe and dispense these medicines.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205747

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy OSCEs

    Pharmacy OSCEs

    The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.

    £25.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Handbook of Pharmaceutical Excipients

    Handbook of Pharmaceutical Excipients

    The Handbook of Pharmaceutical Excipients contains essential data on the physical properties of excipients, their safe use and potential toxicity.

    £415.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.